RxDoctor Payments Data

Robert Walton, NP

Family · Greenville, SCNPI 1922600519

Payments from drug & device makers

$3,509in general payments, 2019–2025

Across 72 payments — averaging $48.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Coloplast$659
  • EDAP Technomed Inc$396
  • Boston Scientific$389
  • Endo USA, Inc.$170
  • 180 Medical, Inc.$132
  • plus $507 from 13 others

What the payments were for

  • Travel & lodging$52215%
  • Food & beverage$2,98785%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,509 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$138,563
Medicare patients
412
Services billed
37,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron72$37,908
GemtesaVibegron12$10,525
Tamsulosin Hcl209$2,467
Finasteride111$986
Testosterone Cypionate31$882
Oxybutynin Chloride ErOxybutynin Chloride28$797
Cephalexin23$207
Alfuzosin Hcl ErAlfuzosin Hcl16$193
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$173
Ciprofloxacin Hcl53$144
Oxycodone Hcl28$70
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$64
Tramadol Hcl20$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$38$37,90872 claims
Sumitomo Pharma America, Inc.Gemtesa$34$10,52512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →